ImmunityBio, Inc. IBRX Reportable Segment — Interest and investment income, net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GainLossOnInvestments.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s reportable segment — interest and investment income, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s reportable segment — interest and investment income, net?
- ImmunityBio, Inc. (IBRX) reported reportable segment — interest and investment income, net of $2.31M in Q1 2026.
- How has ImmunityBio, Inc.'s reportable segment — interest and investment income, net changed year-over-year?
- ImmunityBio, Inc.'s reportable segment — interest and investment income, net increased by 160.9% year-over-year, from $887K to $2.31M.
- What is the long-term trend for ImmunityBio, Inc.'s reportable segment — interest and investment income, net?
- Over 2 years (2023 to 2025), ImmunityBio, Inc.'s reportable segment — interest and investment income, net has grown at a 138.0% compound annual growth rate (CAGR), from $1.13M to $6.41M.
- What does reportable segment — interest and investment income, net mean?
- Reflects the net income earned from cash balances, short-term investments, and other financial assets held by a specific business segment. It represents non-operating income derived from the company's treasury management activities.